Danish drugmaker Novo Nordisk has mitigation plans in place to minimize or prevent any disruption to its production due to ...

State workers’ access to weight loss drugs has put House Speaker Tim Moore at odds with State Treasurer Dale Folwell, who ran ...

The maker of popular drugs, Wegovy and Ozempic, plans to ship its products to and from the U.S. via air freight, the report ...

The longshoreman’s strike shutting down ports along the East and Gulf Coasts may cause a significant shortage of widely used ...

The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.

Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 ...

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

Novo Nordisk said that the launch of Wegovy had “unlocked” the obesity market, despite well-documented supply constraints, but that it is now expanding its focus beyond weight loss to ...

Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...

An analyst waxed bullish on the company's leading pipeline program.

Click here to view the custom infographic of the Annovis Bio editorial. Clickhere  to view the custom infographic of theAnnovis Bioeditorial. Buntanetap vs. AD Annovis Bio Inc. (NYSE: ANVS)  is at the ...